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ABSTRACT  60 
Context: 46,XY gonadal dysgenesis (GD) is a heterogeneous group of disorders with 61 
a wide phenotypic spectrum, including embryonic testicular regression syndrome 62 
(ETRS). Most patients with GD remain without a molecular diagnosis. Objective: To 63 
report a novel gene for 46,XY GD etiology, especially for ETRS. Design: Screening 64 
of familial cases of 46,XY GD using whole exome sequencing and sporadic cases by 65 
target gene panel sequencing. Setting: Tertiary referral center for 66 
Differences/Disorders of sex Development (DSD). Patients and methods: We 67 
selected 87 patients with 46,XY DSD (17 familial cases from eight unrelated families 68 
and 70 sporadic cases); 55 patients had GD (among them, ten patients from five families 69 
and eight sporadic cases had ETRS) and 32 patients had 46,XY DSD of unknown 70 
etiology. Results: We identified four heterozygous missense rare variants classified as 71 
pathogenic or likely pathogenic in DEAH-box helicase 37 (DHX37) gene in five families 72 
(n=11 patients) and in six sporadic cases. Two variants were recurrent: the p.Arg308Gln 73 
(in two families and in three sporadic cases) and the p.Arg674Trp (in two families and 74 
in two sporadic cases).  75 
The variants were specifically associated with ETRS (7/14 index cases; 50%). The 76 
frequency of rare, predicted to be deleterious DHX37 variants in this cohort (0.14) is 77 
significantly higher than that observed in gnomAD population database (0.004; 78 
p<0.001). Immunohistochemistry analysis in human testis showed that DHX37 is 79 
mainly expressed in germ cells, at different stages of testis maturation, in Leydig cells 80 
and rarely in Sertoli cells. Conclusion: This strong genetic evidence identifies DHX37 81 
as a new player in the complex cascade of male gonadal differentiation and 82 
maintenance.  83 




46,XY gonadal dysgenesis (GD) represents a heterogeneous group of 86 
disorders/differences of sex development (DSD) characterized by abnormal gonadal 87 
development leading to a wide phenotypic spectrum. Variable degrees of external 88 
genitalia undervirilisation are observed, ranging from micropenis to female-like genitalia 89 
and partially- or fully-developed Mullerian derivatives.The gonads from these patients 90 
display a wide spectrum of histological abnormalities, ranging from ovarian-like stroma 91 
with disorganized seminiferous tubules to complete absence of gonadal tissue (1). 92 
Embryonic testicular regression syndrome (ETRS) is considered a part of the clinical 93 
spectrum of 46,XY gonadal dysgenesis (2). Most individuals with ETRS present with 94 
micropenis or atypical genitalia and lack of gonadal tissue on one or both sides (2). 95 
Partial or complete Mullerian duct regression associated with micropenis suggests an 96 
intrinsically functional testis in the first months of fetal life subsequent loss of testicular 97 
function before the last trimester of gestation, when the increase in penile length occurs. 98 
Numerous genes are known to be involved in the process of gonadal determination (3). 99 
However, a genetic diagnosis is identified in less than 40% of the patients with 46,XY 100 
GD (4). Moreover, few patients with ETRS were included in large cohorts of 46,XY DSD 101 
previously studied (4). However, the fact that some familial cases of ETRS were reported 102 
indicates a genetic etiology (5,6).  103 
In the present work, high throughput parallel sequencing methods, including whole-104 
exome sequencing (WES) and targeted DSD-gene panels, were used to investigate the 105 
underlying genetic etiology in a large cohort of 46,XY patients with GD and 46,XY DSD 106 
patients with unknown etiological cause.  107 
 6 
 
We identified recurrent rare variants in DEAH (Asp-Glu-Ala-His) box polypeptide 37 108 
(DHX37) in several affected individuals from distinct families, establishing a novel 109 
genetic cause for 46,XY gonadal dysgenesis spectrum, including ETRS. 110 
Ethics 111 
This study was approved by the Ethics Committee of the Hospital das Clínicas da 112 
Faculdade de Medicina da Universidade de São Paulo, the Institutional Review Board of 113 
the University of Michigan Medical School, the Hospital de Garrahan Escuela de 114 
Medicina, Pontificia Universidad Católica de Chile, and the Hospital Nacional Prof. Dr. 115 
A. Posadas, Buenos Aires, Argentina. Written informed consent was obtained from all 116 
patients, their parents or legal guardians.  117 
Subjects and Methods 118 
We studied eighty-seven 46,XY DSD patients without previous molecular diagnosis, 119 
including 17 familial cases of 46,XY GD from 8 non-consanguineous families and 70 120 
sporadic cases (38 with GD and 32 with 46,XY DSD of unknown etiology). Out of the 121 
55 patients with GD, 10 patients from 5 families and 8 sporadic cases had an ETRS 122 
phenotype. The patients had different nationalities: Brazilian (81 patients), Argentinian 123 
(three siblings), Chilean (two siblings) and Chinese-American (one patient). 124 
All patients have a normal GTG-banded metaphases 46,XY karyotype. 125 
The 46,XY DSD patients were classified as having complete GD (CGD) if they had 126 
female external genitalia, Mullerian derivatives and streak gonads; as partial GD (PGD) 127 
if they had atypical external genitalia, Mullerian derivatives and at least one gonad with 128 
histopathological features of dysgenetic testis; as ETRS if they had micropenis, partially 129 
developed Mullerian derivatives and no gonadal tissue or small area of gonadal stroma; 130 
and as 46,XY DSD of unknown etiology if hormonal profile was not conclusive or not 131 
available due to previous gonadectomy. In this latter group, molecular defects of LHCG 132 
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and androgen receptors, CYP17A1, HSD17B3, HSD3B2, and 5ARD2 genes were ruled 133 
out by DNA sequencing.  134 
Genomic DNA  135 
For molecular diagnosis, genomic DNA was extracted from peripheral blood leukocytes 136 
by the proteinase K-SDS salting-out method (7). 137 
Genetic study 138 
Whole exome sequencing (WES) was performed in 14 familial cases from 7 families. In 139 
all but one family, the probands and their first-degree relatives and other affected family 140 
members were studied.  141 
Sixty-eight sporadic cases were studied by targeted massively parallel sequencing. 142 
DHX37 was studied by Sanger sequencing in two sporadic cases and in three patients 143 
from Family 2 (Figure 1). (Supplementary information, in DOI: 144 
10.13140/RG.2.2.35903.76968). 145 
Enrichment for massively parallel sequencing was performed with Nextera Exome 146 
Enrichment Kit (Illumina, San Diego, CA), followed by paired-end sequencing on the 147 
Illumina HiSeq 2500 System (Illumina, San Diego, CA)  148 
For target sequencing, we designed an amplicon-based capture panel against exonic 149 
regions of 63 genes, including 43 genes known to be associated with human DSDs and 150 
20 candidate genes, including DHX37 (3) (see Table S1, Supplementary information 151 
in  DOI: 10.13140/RG.2.2.35903.76968). Target sequences were captured using a custom 152 
Sure Select Target Enrichment System Kit (Agilent Technologies, Santa Clara, CA, 153 
USA) and sequencing was performed on the Illumina MiSeq platform (San Diego, CA, 154 
USA). 155 
Sanger sequencing was used to confirm the potentially pathogenic variants identified by 156 
massively parallel sequencing and for segregation analysis. Sequencing was performed 157 
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on the ABI 3730XL DNA Analyzer (Applied Biosystems) using the BigDye (Applied 158 
Biosystems), followed by data analysis using a Genetic Analyzer (ThermoFisher 159 
Scientific). 160 
The identified variants were classified according to American College of Medical 161 
Genetics (ACMG) criteria (8). 162 
Data analysis 163 
The exome and the targeted panel sequencing data were screened for rare variants (minor 164 
allele frequency < 0.1% in the public databases: Genome Aggregation Database 165 
(gnomAD) (9),  1000 Genomes (10), and in the Brazilian population database (ABraOM) 166 
(11), located in exonic and consensus splice site regions. Subsequently, the filtration 167 
pipeline prioritized potentially pathogenic candidate variants (loss of function variants 168 
and variants classified as pathogenic by multiple in silico programs). For variants 169 
identified by WES, we selected variants that fitted an autosomal-dominant model. 170 
The sequencing reads carrying candidate variants were visually confirmed using the 171 
Integrative Genomics Viewer (Broad Institute, Cambridge, MA). Candidate variants were 172 
segregated in the family members by Sanger method. 173 
The filtering of the variants is provided in Supplementary data (Figure S1) DOI: 174 
10.13140/RG.2.2.35903.76968) 175 
Histological analysis 176 
Immunohistochemical staining 177 
Eight formalin-fixed paraffin-embedded testicular autopsy samples from 46,XY 178 
individuals with different chronological ages (27 and 33 weeks gestational age, 1, 53, and 179 
180 days of age, 13, 23 and 53 years of age) were collected and used for DHX37 180 
expression analysis by immunohistochemistry. All samples were sliced into 3-μm-thick 181 
sections using an automatic Leica RM2255 microtome (Leica Biosystems, Nussloch, 182 
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Germany). The sections were briefly stretched in xylol at 600°C for 20 min, cooled in 183 
xylol, and dried in an incubator (Fanem Orion 515, São Paulo, Brazil) at 600oC. Sections 184 
were subjected to hematoxylin-eosin (HE) staining for histological analysis. For 185 
immunohistochemical study, slides were deparaffinized with xylene, hydrated in ethanol, 186 
washed in phosphate-buffered saline (0.01 M/pH 7.4), and blocked using methanol and 187 
hydrogen peroxide. Epitope exposure was carried out by placing the slide in boiling 10 188 
mM citric acid (pH 6) or 100 mM EDTA (pH 9), followed by blocking non-specific 189 
protein. Rabbit polyclonal anti-DHX37 antibody (NB110-40581; Novus Biologicals, 190 
USA) was added at a dilution factor of 1:50. Dilution was standardized after testing on 191 
ovarian and skin tissues where protein expression was identified in cytoplasm of oocytes 192 
and nuclear membranes of ovarian stromal and squamous cells. The samples were 193 
incubated with universal secondary antibodies using the Novo Link Detection Systems 194 
kit (Leica Biosystems, USA) according to the manufacturer’s instruction.  195 
Statistical analysis 196 
To test the genetic evidence for the association between DHX37 and GD phenotype, we 197 
performed aggregate variant analyses comparing allele frequencies among our 46,XY 198 
DSD cohort and public databases [gnomAD  and ABraOM]. 199 
Variants with similar characteristics of the DHX37 variants observed in our cohort (rare 200 
nonsynonymous variants with a minor allele frequency of 0.01 and located in the two 201 
highly conserved protein (ATP-binding and Helicase C-terminal domains) that are 202 
predicted to be pathogenic by at least four in silico tools (Mutation Taster, SIFT, 203 
PolyPhen-2, Mutation Assessor and PROVEAN) were selected. Allele frequency 204 
differences between groups were analyzed by X2 test, and statistical significance was set 205 
at p<0.05. Statistical analyses were performed using SIGMAstat statistical software 206 






Patient phenotype and DHX37 variants 211 
Firstly, WES identified the same DHX37 variant p.Arg308Gln (c.923G>A) (GenBank: 212 
NM_032656.3) in heterozygous state in two unrelated Brazilian families with ETRS 213 
(Families 1 and 2). All the affected individuals have the same phenotype (micropenis and 214 
absence or bilateral rudimentary gonadal tissue) (Figure 1, Table 1). A founder effect for 215 
p.Arg308Gln variant was ruled out in Families 1 and 2.  216 
The p.Arg308Gln variant was also identified by WES in a Chinese-American sporadic 217 
case of ETRS from Michigan University performed in Eric Vilain’s laboratory (sporadic 218 
case F6:II-1, Figure 1, Table 2).  219 
As a novel candidate gene for 46,XY DSD, DHX37 was included in our target DSD-220 
panel. The same p.Arg308Gln variant was identified in another two sporadic cases: one 221 
had ETRS (sporadic case F7:II-1) and the other had PGD (sporadic case F8:II-1) (Figure 222 
1; Table 2). 223 
A further three different heterozygous DHX37 missense variants (the p.Arg674Trp, 224 
p.Ser595Phe and p.Thr304Met) were identified in seven affected members from three 225 
families and in three sporadic cases (Figure 2).  226 
All of these four variants are predicted to be pathogenic by at least four in-silico 227 
prediction tools (Table 3) and are absent in genomic population databases, except for the 228 
p.Arg308Gln, which has a very low allele frequency (0.00003) in the gnomAD database 229 
(Tables 4-5).  230 
The p.Arg674Trp (c.2020C>T) variant was identified in the two Chilean brothers, both 231 
with ETRS (cases F3:II-1 and F3:II-2, Family 3), and also in the three Argentinian 232 
affected members (two brothers with ETRS and their uncle with PGD; cases F4:III-1, 233 
F4:III-2 and F4:II-4, respectively, Family 4) (Figure 1, Table 1). In addition, the 234 
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p.Arg674Trp variant was also identified in another two Brazilian sporadic cases, one 235 
patient with ETRS (sporadic case F10:II-1) and the other with PGD (sporadic case F11:II-236 
1) (Figure 1, Table 2) 237 
The p.Ser595Phe (c.1784C>T) variant was identified in two affected individuals from the 238 
same Brazilian family (Family 5). The proband had PGD and her nephew had ETRS 239 
(F5:II-6 and F5:III-1, respectively) (Figure 1,Table 1). 240 
The p.Thr304Met (c.911C>T) was identified in a Brazilian female (sporadic case F9: II-241 
5), who had previously undergone bilateral gonadectomy and genitoplasty (Figure 242 
1,Table 2).  243 
The p.Arg308Gln variant is classified as pathogenic and the other three variants, 244 
p.Arg674Trp, p.Ser595Phe and p.Thr304Met, are classified as likely pathogenic 245 
accordingly the ACMG criteria (Tables 4-5).  246 
Segregation analysis of DHX37 variants 247 
Segregation analysis of the DHX37 variants in eight families displayed a sex-limited 248 
autosomal dominant pattern, maternally inherited in five families (F2, F3, F4, F5, F11). 249 
In the Family 1, the presence of the p.Arg308Gln variant in the asymptomatic father 250 
suggests an autosomal dominant pattern of inheritance with incomplete penetrance 251 
(Figure 1). In two sporadic cases (F6. II-1 and F8.II-1), the confirmed paternity displayed 252 
a de novo status of the p.Arg308Gln DHX37 variant. 253 
DHX37 gene and its protein structure 254 
DHX37 is located in the 12q24.31 region. It is a member of the large DEAH family of 255 
proteins and encodes an RNA helicase (12). The DHX37 protein (NP_116045) comprises 256 
1157 amino acids and four main domains. The conserved motifs of the helicase core 257 
region contain the Helicase ATP-binding domain (position 262-429) and the Helicase 258 
superfamily c-terminal domain (position 585-674); the two other domains are the helicase 259 
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associated domain (position 768-859) and the oligonucleotide/oligosaccharide-binding-260 
fold domain (position 894-1011) (Figure 2). All the identified variants are located in the 261 
helicase core region (Figure 2).  262 
DHX37 protein was identified in different testicular cells  263 
DHX37 expression was characterized in testes from newborns, children and adults using 264 
immunohistochemistry. DHX37 was expressed in fibroblasts, endothelial cells and 265 
epithelial cells of epididymis. These cells were used as internal positive controls for 266 
immunohistochemistry. We found DHX37 expression in Leydig cell cytoplasm and in 267 
germ cells at different stages of maturation. Our analysis indicates that DHX37 268 
expression in spermatogonia is characterized by a regular perinuclear halo pattern in both 269 
newborns (five samples) and adults (three samples). This pattern of staining differs from 270 
that seen in Leydig cells (granular cytoplasmatic) and during other stages of maturation 271 
of germ cells. A progressive condensation of protein around the nucleus was observed as 272 
cells differentiate from spermatocytes to spermatids, generating a localized paranuclear 273 
dot-like pattern. There was no staining in spermatozoa. Rare Sertoli cells displayed a 274 
weak and focal cytoplasmatic stain (Figure 3).  275 
Frequency of the DHX37 variants in our 46,XY DSD cohort 276 
The allele frequency of rare and predicted to be deleterious DHX37 variants identified in 277 
our cohort of 46,XY DSD patients [11/78 index cases (0.14)] was markedly higher than 278 
that observed in individuals from gnomAD [568 /141456 individuals (0.004; p<0.001)] 279 
and from a Brazilian cohort [1/609 individuals (0.002); p<0.001)].  280 
 281 
Discussion 282 
The present study analyzed a large cohort of 46,XY DSD patients without a molecular 283 
diagnosis, most of whom had a GD phenotype, including a large number of familial and 284 
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sporadic cases with ETRS. 285 
Pathogenic or likely pathogenic allelic variants in the DHX37 were identified in 11 286 
familial cases from 5 unrelated families and in six sporadic cases. Deleterious variants 287 
are recurrent in familial and sporadic cases of 46,XY GD in patients of different 288 
nationalities.  289 
The DHX37 gene has never been directly associated with gonadal development, but 290 
deletions or rearrangements of the 12q24 chromosomal region, which contains DHX37 291 
gene, have been associated with atypical genital development (13). Four syndromic 292 
patients with micropenis or perineal hypospadias, and/or hypergonadotropic 293 
hypogonadism are reported to have deletions or rearrangements involving the 12q24 294 
region (13-15).  295 
The DHX37 gene encodes a RNA helicase protein which is involved in RNA-related 296 
processes, including transcription, splicing, ribosome biogenesis (16), translation and 297 
degradation (12,17). DHX37 is required for maturation of the small ribosomal subunit in 298 
human cells, through its catalytic activity, required for dissociation of the U3 snoRNA 299 
from pre-ribosomal complexes (18). Disturbance of human ribosome production is 300 
associated with cancer and genetic diseases known as ribosomopathies (19). 301 
Disease-causing variants in the DExH-box helicase 30 (DHX30), were previously 302 
described in syndromic patients with global developmental delay, intellectual disability, 303 
severe speech impairment and gait abnormalities. Functional studies of allelic variants in 304 
DHX30 demonstrated that they affect protein folding or stability interfering with the RNA 305 
binding (mutations located in Motif Ia) or with ATPase activity (mutations located in 306 
Motif II and VI) (17,18). Two DHX37 allelic variants found in the present study are 307 
located in the same motifs. 308 
Despite lack of experimental evidence to formally demonstrate the deleterious effects of 309 
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the four variants identified in the present study, they are located in the highly conserved 310 
helicase core region of the DHX37 protein.  311 
The spontaneous p.Leu489Pro Dhx37 pathogenic variant was identified in Zebrafish in 312 
association with behavior scape defects (20). This study demonstrated that Dhx37 is 313 
involved in pre-mRNA splicing reinforcing the role of Dhx37 in RNA-related processes.  314 
Although there is no direct evidence of DHX37 being involved in mRNA processing 315 
during gonadal development, DExD/H-box RNA helicase genes are differentially 316 
expressed between males and females during the critical period of male sex differentiation 317 
in channel catfish (21).  318 
Further, we show population evidence that the DHX37 variants are enriched among the 319 
46,XY GD patients in comparison with the population database. The statistical analysis 320 
confirmed that the predicted deleterious DHX37 variants located in the helicase core 321 
region are more frequently identified in our 46,XY DSD cohort than in the public 322 
databases, emphasizing that this finding was not by chance (p<0.01).  323 
Therefore, in vitro and in vivo studies on DHX37 mechanism have demonstrated a role 324 
of DHX37 in ribosome biogenesis (23). Based on this new knowledge, 46,XY gonadal 325 
dysgenesis could be classified as a ribosomopathy, expanding the etiological mechanisms 326 
of dysgenetic 46,XY DSD spectrum. 327 
Since the discovery of the sex-determining region Y (SRY) variants in patients with GD 328 
in 1990 (22), several genes have been associated with the molecular etiology of this 329 
disorder. The nuclear receptor subfamily 5 group A member 1 (NR5A1) and Mitogen-330 
Activated Kinase Kinase Kinase 1 (MAP3K1) variants are the most frequent causes of 331 
46,XY gonadal dysgenesis identified to date (23-26). 332 
In this study we found pathogenic/ likely pathogenic variants in DHX37 in patients with 333 
46,XY GD at a frequency of 14%, which is slightly higher than the frequency of NR5A1 334 
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defects (11%) in our whole cohort (24,27). Considering only the ETRS phenotype 335 
(micropenis and absence of uni or bilateral testicular tissue) this frequency increases to 336 
50% (7/14 families). 337 
In the literature, different inheritance patterns have already been described in 46,XY 338 
gonadal dysgenesis kindreds (28), including the description of asymptomatic male 339 
carriers of proven pathogenic variants of genes involved in testicular determination, such 340 
as SRY and NR5A1 genes (29,30). Uncertain mechanisms might prevent the appearance 341 
of the phenotype in asymptomatic 46,XY carriers.  342 
Maternal inheritance was observed in all familial cases with pathogenic/ likely pathogenic 343 
variants in DHX37 with the exception of family 1, where the variant was inherited from 344 
a seemingly unaffected father carrier. 345 
In adult humans, the DHX37 protein is expressed in the ovarian stroma and in the cells 346 
within seminiferous tubules (Human Protein Atlas database) (31-33). In our study, the 347 
immunohistochemistry analysis of normal testicular tissue from newborn, pubertal and 348 
adult males revealed that DHX37 is expressed during specific stages of germ cell 349 
maturation, in Leydig cells and rarely in Sertoli cells.  350 
An elaborate paracrine cell-cell network transporting signaling molecules between germ 351 
cells and Sertoli cells has been described (34). Indeed, in vitro studies have shown that 352 
there is a bidirectional trafficking between Sertoli and germ cells, and that each cell type 353 
regulates the function of the other (35-38). In addition, RNA expression profiles of 354 
DHX37 in human testicular cancer cells are higher than in other tissues (The Human 355 
Protein Atlas – Pathology), suggesting that DHX37 may be involved in the regulatory 356 
process of the cell proliferation in the testis (31-33). 357 
The present study provides several lines of genetic evidence to indicate that defects in 358 
DHX37 are associated with 46,XY GD spectrum, mainly with ETRS. First, we observed 359 
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that the variants segregate with the DSD phenotype in a dominant inheritance pattern in 360 
most of the families and that two de novo variants were identified. Second, we provide 361 
statistical evidence that rare DHX37 variants are enriched in the analyzed 46,XY DSD 362 
cohort in comparison with public databases involving a large number of individuals not 363 
selected by this phenotype. 364 
In conclusion, our findings indicate that DHX37 is a new player in the complex cascade 365 
of male gonadal differentiation and maintenance, thus establishing a novel and frequent 366 
molecular etiology for 46,XY gonadal dysgenesis spectrum, which includes a high 367 
proportion of individuals with embryonic testicular regression syndrome. 368 
Supplementary information:  displayed in DOI: 10.13140/RG.2.2.35903.76968).   369 
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Table 1. Phenotype of 46,XY DSD patients with familial embryonic testicular regression syndrome with rare and predicted pathogenic or likely pathogenic DHX37 553 
variants 554 








Patient F1:III-2 F1:III-3 F2:II-4 F2:III-1 F3:II-1 F3:II-2 F4:III-1 F4:III-2 F4:II-4 F5:II-6 F5:III-1 
Sex of rearing Male Male Male Female Male Male Male Male Male Female Male 
Age at presentation 
(yrs) 
2.2 1.8 14.0 1.8 0.6 24 days Newborn 4 2 18 10 
Diagnosis ETRS ETRS ETRS ETRS ETRS ETRS ETRS ETRS PGD PGD ETRS 
External genitalia Micropenis Micropenis Micropenis Micropenis Micropenis Micropenis Micropenis Micropenis Micropenis Atypical Micropenis 
Gonads Non-palpable Non-palpable Non-palpable Non-palpable Non-palpable Non-palpable Non-palpable Non-palpable 






























Right gonad not 
found 
Left dysgenetic 






Wolffian derivatives Present Present Present Present Present Present Present Present Present Present Present 
Mullerian 
Derivatives 
Tubes Present¥ Absent Present¥ Present¥ Absent Present Present¥ Present¥ Absent Absent Absent 
Uterus Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent Absent 
LH (IU/L) 14.5 12 3.5 1.9 <0.5 <0.5 <0.5 <0.5 26 NA 19 
FSH (IU/L) 117 133 87 56 10.9 9.5 NA 9 112 NA 43 
Basal  
Testosterone (ng/dL) 
<10 <10 <10 NA 16 <10 38 27 16 NA 21 
Testosterone  
after hCG test (ng/dL) 
<10 NA 29 26 18 <10 40 29 NA NA NA 
Allelic variant p.Arg308Gln p.Arg308Gln p.Arg308Gln p.Arg308Gln p.Arg674Trp p.Arg674Trp p.Arg674Trp p.Arg674Trp p.Arg674Trp p.Ser595Phe p.Ser595Phe 
Variant state Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous 
NA- not available; PGD- partial gonadal dysgenesis; GCNIS - germ cell neoplasia in-situ; * testicular biopsy; ¥ - Rudimentary Fallopian tubes;  555 






Table 2. Phenotype of 46,XY DSD patients with sporadic gonadal dysgenesis spectrum and heterozygous rare pathogenic or likely pathogenic DHX37 variants 560 




Patient F6:II-1 F7:II-1 F8:II-1 F9:II-5 F10:II-1 F11:II-1 
Social sex Male Male to Female Female Female Male to female Female 
Age at presentation (yrs) 0.18 30 7.7 35 19 3.7 




External genitalia Micropenis Micropenis Female Previous genitoplasty Micropenis Atypical 












Wolff derivatives Present Present Present  NA NA Present 
Mullerian 
derivatives 
Tubes Absent Present Absent NA Absent Present 
Uterus Absent Absent Absent Absent Absent Absent 
LH (IU/L) 0.1 10 0.1 NA 23 NA 
FSH (IU/L) 0.4 40 4.9 NA 62 NA 
Basal  
Testosterone (ng/dL) 
<10 NA <10 NA 21 25 
Testosterone 
after hCG test (ng/dL) 
<10 <10 NA NA NA 33 
Allelic variant p.Arg308Gln p.Arg308Gln p.Arg308Gln p.Thr304Met p.Arg674Trp p.Arg674Trp 
Variant state Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous Heterozygous 
NA: not available; PGD- Partial gonadal dysgenesis; Conversion factors to SI units: T, ng/dL to nmol/L, multiply by 0.0347.  561 
  562 
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De novo  
data 
Other data Classification 
F1, F2, 
F6, F7, F8 




PS2 d PM1e Pathogenic 
F3, F4, 
F10,F11 




















PM2: moderate piece of evidence for pathogenicity; PP3: supporting evidence for pathogenicity by computational (in silico) data;  
PS2: strong support for pathogenicity when the variants are de novo; PP4: supporting evidence using phenotype; PM1: pathogenic moderate;  
VUS: Variant of Uncertain Significance. 
a Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. 
b Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease 
c Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.) 
d  De novo (both maternity and paternity confirmed) in a patient with the disease and no family history. 






Figure 1. Pedigrees of the eleven families with potential disease-causing DHX37variants. Filled symbols represent affected individuals. The affected males (46,XY males) are 572 
indicated by filled squares and the affected individuals raised as females (46,XY females) are shown by large dark dots within the squares. Symbols with a diagonal line 573 
represent deceased individuals. The DHX37 genotype is shown for the individuals whose DNA sample was available; +/- indicates a heterozygous state and -/- indicates a 574 
homozygous state for wild-type allele. NA- DNA not available. Paternity and maternity was confirmed in families 6 and 8. 575 





Figure 2. The identified variants are localized within conserved helicase domains of DHX37. Top: Schematic protein structure of DHX37 showing conserved 578 
motifs of the helicase core region, the helicase associated domain (HA2) and the oligonucleotide/oligosaccharide-binding-fold. Middle: Nucleotide-interacting 579 
motifs (I, II, and VI), nucleic acid-binding motifs (Ia, Ib, and IV), motif V, which binds nucleic acid and interacts with nucleotides, and motif III, which couples 580 
ATP hydrolysis to RNA unwinding (N- N terminus; C- C terminus). Bottom: Amino acids within conserved motifs of the helicase core region. The position of 581 
the first and last amino acid within each motif is denoted below left and right, respectively. The position of the allelic variants identified in this study are 582 




PRRVAAVGETGSGKT TDGVL SATDEAH LVFLTGQA TNVAETSLT QRAGRAGR






585 674262 429 768 859 894 1011 
N - - C





































Figure 3. Immunoexpression patterns of DHX37 in testis tissues. A- Newborn testis showing 586 
strongly positive staining in occasional spermatogonia (arrow) among numerous Sertoli cells, 587 
some of which show weak cytoplasmic staining (original magnification 100X). B- 588 
Seminiferous tubules of a 13 year old boy demonstrating tubules with predominance of Sertoli 589 
cells, all of them negative for DHX37. Note some positive stromal cells (arrow) (original 590 
magnification 100X).  C- Adult testis of a 54 year old man showing positive Leydig (arrow) 591 
and germ cell staining. D- Detail of (C) showing the different pattern of stain in different stages 592 
of germ cells. Note strong perinuclear halo in spermatogonia, progressive paranuclear 593 
condensation in spermatocytes and spermatids, and absence of DHX37 expression in 594 
spermatozoa (original magnification ×20X.595 
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